At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 53 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Placebo 0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
In Brief
A Phase 2 clinical trial evaluating Placebo, PF-06835919 Low Dose, and 1 other intervention for Non-alcoholic Fatty Liver Disease. Completed, enrolled 53 participants across 9 sites.
Detailed Summary
IN THIS PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, 3 ARM, PARALLEL- GROUP STUDY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS WILL BE ASSESSED IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-alcoholic Fatty Liver Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartSep 2017
Primary CompletionMar 2018
Study CompletionApr 2018
TodayJul 2026
First PostedAug 22, 2017
Enrollment StartSep 27, 2017
Primary CompletionMar 30, 2018
Study CompletionApr 27, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.9 years ago
Interventions
Placebodrug
0 mg
PF-06835919 Low Dosedrug
75 mg once daily
PF-06835919 High Dosedrug
300 mg once daily